Vanta Bioscience Limited (BOM:540729)

India · Delayed Price · Currency is INR

22.83

0.00 (0.00%)

At close: Aug 5, 2026

Vanta Bioscience Financials Overview

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	18.16	18.16	19.64	97.23	62.76	100.18
Revenue Growth	47.09%	-7.49%	-79.81%	54.93%	-37.35%	-0.33%
Gross Profit	27.09	27.09	4.25	88.74	52.85	92.03
Operating Income	6.32	6.32	-86.72	-31.68	-50.64	24.83
Net Income	1.08	1.08	-47.75	-23.16	-64.81	0.88
Earnings Per Share	0.15	0.15	-7.56	-3.67	-10.27	0.14
EPS Growth	-	-	-	-	-	-80.38%

Revenue by Geography

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
India	4.91	19.91	41.23	23.79
Export	14.73	77.32	21.53	53.47
Total	19.64	97.23	62.76	96.87

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Investments	1.35	1.35	2.22	1.61	0.97	2.24
Total Debt	380.78	380.78	700.84	609.54	571.61	448.67
Net Cash (Debt)	-379.43	-379.43	-698.62	-607.93	-570.65	-446.43
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-52.55	-52.55	-110.68	-96.31	-90.41	-70.73

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Cash Flow	-52.19	-52.19	-24.09	26.84	-6.28	52.79
Capital Expenditures	-68.72	-68.72	-66.94	-34.05	-286.89	-171.81
Free Cash Flow	-120.92	-120.92	-91.02	-7.21	-293.17	-119.02
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Gross Margin	149.14%	149.14%	21.67%	91.27%	84.21%	91.86%
Operating Margin	34.77%	34.77%	-441.66%	-32.58%	-80.69%	24.78%
Pretax Margin	0.75%	0.75%	-643.17%	-90.78%	-163.53%	2.28%
Profit Margin	5.96%	5.96%	-243.18%	-23.82%	-103.26%	0.88%
FCF Margin	-665.70%	-665.70%	-463.56%	-7.41%	-467.13%	-118.81%

Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug '26 Aug 6, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
PE Ratio	152.20	88.30	-	-	-	786.08
PS Ratio	7.93	5.27	7.11	4.16	5.78	6.92